Research News
View articles by month and year
-
Experimental Osteoporosis Medicine May Reduce Breast Cancer Risk
An experimental osteoporosis medicine has been shown to reduce the risk of breast cancer in postmenopausal women.
-
Arimidex Still Better Than Tamoxifen After Surgery to Reduce Recurrence Risk
After 10 years of follow-up, research shows that 5 years of Arimidex is better at reducing the risk of hormone-receptor-positive breast cancer recurrence than 5 years of tamoxifen.
-
Aromatase Inhibitor Before Surgery May Make Lumpectomy an Option
Many women diagnosed with hormone-receptor-positive, early-stage breast cancer for whom mastectomy was recommended may be candidates for lumpectomy after taking an aromatase inhibitor.
-
New Guidelines Prefer Aromatase Inhibitors Over Tamoxifen
The American Society of Clinical Oncology has issued new guidelines on taking hormonal therapy medicines after breast cancer surgery.
-
Tamoxifen and Evista Both Good Choices to Reduce Risk
Both tamoxifen and Evista lower the risk of invasive and non-invasive breast cancer in women at high risk, and each medicine has benefits and risks.
-
Beta-Blocker Seems to Reduce Risk of Metastatic Spread
New research suggests that beta-blockers may improve breast cancer prognosis.
-
Taking Antidepressant with Tamoxifen Reduces Tamoxifen’s Effectiveness
Research suggests that women taking the antidepressant Paxil at the same time as the hormonal therapy medicine tamoxifen are more likely to die from breast cancer than women taking tamoxifen who never took Paxil.
-
High-Dose Vitamin D May Ease Joint Pain from Arimidex
A small study suggests that very high doses of vitamin D taken each week may help ease muscle and joint pain associated with Arimidex.
-
Radiation and Hormonal Therapy After DCIS Surgery Lowers Recurrence Risk
After DCIS surgery, radiation therapy seems to be better at lowering the risk of cancer in the same breast while hormonal therapy seems to be better at lowering the risk of cancer in the opposite breast.
-
Higher Faslodex Dose More Effective Against Metastatic Breast Cancer
Advanced-stage, hormone-receptor-positive breast cancers treated with 500 mg of Faslodex (double the usual dose) had a slightly better response than cancers treated with 250 mg of Faslodex (the usual dose).
